As US President Donald Trump escalates the war on narcotics with a sweeping designation, South Asia’s role in Trump drug policy comes under intense US scrutiny, what countermeasures will Delhi and Islamabad deploy?
US President Donald Trump on Monday, 15 September, 2025, submitted a Presidential Determination to Congress under his Trump India Pakistan drug policy, naming India and Pakistan among 23 countries as major drug transits or illicit drug producers to address the fentanyl crisis that claims over 200 American lives daily through enhanced international pressure and cooperation.
Why Trump Drug Policy Matters for South Asia
The inclusion of India and Pakistan in this Trump India Pakistan drug policy underscores the region’s strategic vulnerabilities as narcotics hubs, potentially influencing US aid, trade dynamics, and bilateral security pacts amid rising transnational threats. For South Asia, where porous borders facilitate heroin and synthetic drug routes from Afghanistan, this signals a call for bolstered regional enforcement to mitigate reputational risks and foster joint operations against cartels.
Trump India Pakistan Drug Policy: Unveiling the Memorandum
In a formal memorandum released via the US Department of State, President Trump outlined his administration’s aggressive approach to dismantling global drug networks. The document, submitted on Monday, 15 September, 2025, identifies countries based on “geographic, commercial, and economic factors that allow drugs or precursor chemicals to be transited or produced,” emphasising that inclusion does not solely reflect governmental shortcomings.
The full list of 23 nations under this India Pakistan major drug transit Trump framework comprises: Afghanistan, The Bahamas, Belize, Bolivia, Burma, the People’s Republic of China, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, India, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru, and Venezuela.
President Trump highlighted the urgency in a statement: “Transnational organised crime’s trafficking of fentanyl and other deadly illicit drugs into the United States has created a national emergency, including a public health crisis in the United States that remains the leading cause of death for Americans ages 18 to 44. More than 40 percent of Americans know someone who has died from an opioid overdose, and in 2024 the United States averaged over 200 deaths daily due to illicit drugs. This remains unacceptable, and my Administration is deploying every aspect of American power and unprecedented resources to defeat this threat to our Nation.”
This Trump India Pakistan drug policy builds on prior fiscal year assessments but intensifies focus on precursor chemical flows and border vulnerabilities, with the White House Office of National Drug Control Policy poised to enforce accountability measures.
Countries Facing Demonstrable Failure’ Designation
Five nations, Afghanistan, Bolivia, Burma, Colombia, and Venezuela received the stark label of having “failed demonstrably” in the past 12 months to meet international counternarcotic obligations or implement remedial actions. The US determination notes that continued assistance to Bolivia, Burma, Colombia, and Venezuela remains vital to American national interests, despite these lapses. Notably, neither India nor Pakistan falls into this category, suggesting recognition of their ongoing efforts amid the broader India Pakistan major drug transit Trump context.
India Pakistan Major Drug Transit Trump: Regional Ramifications
For India and Pakistan, the designation spotlights their positions along key opium and synthetic drug corridors, particularly heroin routes originating from the Golden Crescent in Afghanistan. The US State Department clarified that such listings prioritise transit risks over cooperation levels, yet they could prompt closer scrutiny of maritime and air routes in the Indian Ocean and Arabian Sea.
India’s Narcotics Control Bureau (NCB) has demonstrated proactive measures, recently dismantling a transnational syndicate smuggling controlled medicines via encrypted platforms, drop shipping, and cryptocurrency across India, the US, Australia, and Europe. The operation, triggered by a vehicle interception near Bengali Market in New Delhi, exposed a network spanning four continentson the 3rd of July 2025.
The US Embassy in New Delhi commended these actions, stating: “Thanks to NCB and Indian authorities for helping protect Americans against illegal drugs and saving American lives!” This underscores potential for deepened Trump India Pakistan drug policy partnerships, even as the listing raises questions about precursor chemical diversions from pharmaceutical hubs.
Pakistan, sharing a 2,640-kilometre border with Afghanistan, faces amplified pressures from opium cultivation spikes, with UN estimates indicating over 10,000 hectares under poppy in 2024. The India Pakistan major drug transit Trump tag may accelerate US-Pakistan dialogues on border fortifications, echoing prior collaborations under the US-Pakistan Comprehensive Security Dialogue.
As of Wednesday, 17 September, 2025, neither the Indian Ministry of External Affairs nor Pakistan’s Foreign Office has issued an official response to the designation.
Background
Annual Presidential Determinations on major drug transits trace back to the Foreign Assistance Act of 1961, evolving under successive US administrations to target the opioid epidemic. The 2026 fiscal year list, the first under Trump’s second term, expands from 22 countries in 2025, reflecting heightened concerns over fentanyl precursors from Asia. Historical data from the US International Narcotics Control Strategy Report (INCSR) highlights South Asia’s role, with India intercepting 2.4 tonnes of heroin in 2024 and Pakistan seizing 25 tones amid rising methamphetamines.
This Trump India Pakistan drug policy aligns with broader executive actions, including tariffs on imports linked to drug flows and enhanced sanctions on cartels, as detailed in White House priorities for 2025.
What’s Next in the Trump India Pakistan Drug Policy
Looking ahead, the US may leverage this framework for targeted aid, such as $50 million in counternarcotics funding for South Asian partners, while monitoring compliance through joint task forces. Regional forums like the Colombo Plan could see renewed vigour, with India and Pakistan potentially leading trilateral initiatives with Afghanistan.
As the Trump India Pakistan drug policy takes shape, it promises to recalibrate South Asia’s defences against the insidious tide of illicit narcotics, demanding unified resolve from Washington, Delhi, and Islamabad to safeguard communities on both sides of the globe.
Published in SouthAsianDesk, September 18th, 2025
Follow SouthAsianDesk on X, Instagram, and Facebook for insights on business and current affairs from across South Asia.
